InnoSIGN
Latest round
- Series A
Last raised
- Mar 2022
Total raised
- $8M
Investors
- 4
About InnoSIGN
V. is a precision medicine firm that focuses on diagnostics and drug development applications.V.V., and Thuja Capital. Paul van de Wiel is the CEO of the company. The company provides OncoSIGNal pathway activity profiling technology, which is based on mRNA, which is transforming precision medicine by providing additional insight into disease causes. The firm utilizes its database with more than 100,000 pathway activity profiles to support diagnostics and drug development. The March 2022 investment supports the organization's clinical validation and US market launch.
Who invested in InnoSIGN
4 investors across 1 round
See all investors in InnoSIGN
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 22, 2022
Amount
$8M
Investors
Questions about InnoSIGN
Who invested in InnoSIGN?
InnoSIGN has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has InnoSIGN raised?
InnoSIGN has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did InnoSIGN last raise money?
InnoSIGN's most recent round on record is a Series A, in Mar 2022.
What does InnoSIGN do?
InnoSIGN is a biotechnology company.
Where is InnoSIGN headquartered?
InnoSIGN is headquartered in Eindhoven, Netherlands.
Which VCs invest in companies like InnoSIGN?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at InnoSIGN's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like InnoSIGN? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.